Issues in the local control of rhabdomyosarcoma
1Division of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0757, USA.
Background:
Rhabdomyosarcoma (RMS) is a heterogeneous disease consisting of several different histologies arising from a variety of anatomic sites. Approximately half of the children who die of this tumor have failure at the primary site of involvement, making local control an important component of therapy.
Procedure:
Published literature and newly analyzed data from the Intergroup Rhabdomyosarcoma Study Group (IRSG) regarding local control of RMS were reviewed. Information regarding the role of various local control modalities for different primary disease sites is presented along with new directions for clinical research.
Results:
Local control rates for RMS average 80% for group III tumors, with large variations seen for different anatomic sites. Important gains in functional outcome for certain sites such as gynecologic system and bladder/prostate have been achieved by optimizing the use of the various treatment modalities. Local control at other sites such as the chest and extremities remains a problem.
Conclusions:
Advances in surgical and radiotherapy techniques coupled with multiagent chemotherapy are providing improved local control with decreasing morbidity. Optimal outcome is dependent on close collaboration between surgical, radiotherapy, and pediatric oncology specialists.
Insights
Achieving local control in rhabdomyosarcoma (RMS) is crucial for survival, with current rates averaging 80%. Advances in treatment are improving outcomes, but challenges remain for specific tumor sites.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Rhabdomyosarcoma Treatment
Background:
- Rhabdomyosarcoma (RMS) is a diverse pediatric cancer with varied histologies and origins.
- Local disease recurrence is a primary cause of mortality in children with RMS.
- Effective local control strategies are essential for improving patient outcomes.
Purpose of the Study:
- To review existing literature and analyze Intergroup Rhabdomyosarcoma Study Group (IRSG) data on local control of RMS.
- To present the role of different local control modalities across various primary tumor sites.
- To identify new directions for clinical research in RMS local control.
Main Methods:
- Comprehensive review of published literature on RMS local control.
- Analysis of newly acquired data from the Intergroup Rhabdomyosarcoma Study Group (IRSG).
- Evaluation of local control rates and treatment modalities for different anatomic sites.
Main Results:
- Average local control rates for rhabdomyosarcoma (RMS) are approximately 80% for group III tumors.
- Significant improvements in functional outcomes observed for gynecologic and bladder/prostate RMS.
- Local control remains challenging for RMS primary sites in the chest and extremities.
Conclusions:
- Multimodal therapy, including surgery, radiotherapy, and chemotherapy, enhances local control and reduces morbidity.
- Optimizing treatment strategies has led to better functional outcomes in specific RMS subtypes.
- Close interdisciplinary collaboration among surgical, radiation oncology, and pediatric oncology specialists is vital for optimal patient care.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...